Cara Therapeutics to Host Virtual Research and Development Event on April 7, 2021
31 mars 2021 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
30 mars 2021 01h00 HE
|
Cara Therapeutics, Inc.
Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalinIf approved, difelikefalin injection will be the first therapy available in Europe for...
Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
08 mars 2021 01h00 HE
|
Cara Therapeutics, Inc.
FDA has set Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients ...
Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
25 févr. 2021 16h01 HE
|
Cara Therapeutics, Inc.
– U.S. FDA Accepts NDA Filing for KORSUVA™ Injection in CKD-aP – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
18 févr. 2021 16h01 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Pruritus in Patients with Notalgia Paresthetica
11 janv. 2021 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
06 janv. 2021 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
28 déc. 2020 07h00 HE
|
Cara Therapeutics, Inc.
First NDA submission for Company’s lead program, KORSUVA™ Injection –NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection – STAMFORD,...
Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
02 déc. 2020 07h00 HE
|
Cara Therapeutics, Inc.
- Topline data expected in first half of 2021 - STAMFORD, Conn., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and...
Cara Therapeutics to Present at Multiple Upcoming Investor Conferences
11 nov. 2020 07h00 HE
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...